Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03428451
Other study ID # N02112
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 10, 2018
Est. completion date December 2018

Study information

Verified date December 2018
Source Kasr El Aini Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to investigate the usage & effects of prophylactic HS preloading, with two different concentrations, to combat the expected dilutional hyponatremia induced by irrigating fluid absorption and to prevent the occurrence of TURP syndrome with its potential complications


Description:

The study will be conducted on 60 patients ASA class I - III BPH patients, candidates for TURP surgery using monopolar electronic resectoscope. Eligible patients will be allocated into one of three study groups (n=20 in each). Group A patients will receive NaCl 3% HS at a dose of 4 ml/kg/hr; Group B patients will receive NaCl 3% HS at a dose of 2 ml/kg/hr; while Group C patients will receive NaCl 0.9% Normal Saline(NS) at a dose of 6 ml/kg/hr. All intra-venous infusions will be started 30 minutes before the subarachnoid block, and continued all through the procedure at the same specific rate for each infusion. Vital signs [mean BP, HR, CVP & oxygen saturation (spO2)] will be recorded. Plasma electrolytes (sodium, potassium, chloride)and serum osmolality (mOsm) will be measured. Incidence of TUR syndrome, need for ICU admission, post-operative ventilation and total hospital stay will be noted.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender Male
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria:

- ASA class I - III BPH patients

Exclusion Criteria:

- Patients having any condition contra-indicating regional anesthesia e.g impaired coagulation.

- Electrolyte imbalance,

- Uncontrolled hypertension,

- Congestive heart failure or being allergic to local anesthetics.

Study Design


Related Conditions & MeSH terms

  • Syndrome
  • Transurethral Resection of Prostate Syndrome

Intervention

Drug:
NaCl 3% HS
Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
NaCl 3% HS
Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
NaCl 0.9% NS
Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.

Locations

Country Name City State
Egypt Faculty of Medicine Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ahmed Mohamed ELbadawy

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum sodium level measured in mEq/L Hyponatremia was defined as a serum sodium < 130 mEq/L 72 hours
Secondary Incidence of TURP syndrome Occurring TURP syndrome manifestations 72 hours
Secondary Need for ICU admission For cardio-pulmonary support(vasopressor,mechanical ventilation), neurological monitoring 72 hours
See also
  Status Clinical Trial Phase
Recruiting NCT04084938 - Artery Embolization vs Operation of Benign Prostate Hyperplasia N/A
Recruiting NCT05531240 - Transurethral Prostate Resection (TURP) vs. Prostate Artery Embolization (PAE) N/A
Active, not recruiting NCT03324477 - The Hemodynamic Effects of Hypertonic Saline Preload Versus Coload Measured by Non-invasive Cardiometry in Patients Undergoing TURP Surgery Phase 4
Completed NCT04047329 - Risk Factors and Impact of Anesthesia Techniques on Myocardial Infarction Following Transurethral Resection of the Prostate